HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

abicipar pegol

a pegylated 34 kDa recombinant ankyrin repeat protein that binds all isoforms of VEGF-A with high affinity and specificity

Networked: 9 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - Recombinant Fusion Proteins: 333
      - abicipar pegol: 9

Experts

1.	Hussain, Rehan M: 2 articles (01/2021 - 01/2020)
2.	Kunimoto, Derek: 2 articles (01/2019 - 12/2018)
3.	Maturi, Raj K: 2 articles (01/2019 - 12/2018)
4.	Schneider, Susan: 2 articles (01/2019 - 12/2018)
5.	Hohman, Thomas C: 2 articles (12/2018 - 12/2018)
6.	Berrocal, Audina M: 1 article (01/2021)
7.	Ciulla, Lauren M: 1 article (01/2021)
8.	Shaukat, Bilal A: 1 article (01/2021)
9.	Sridhar, Jayanth: 1 article (01/2021)
10.	Ferro Desideri, Lorenzo: 1 article (07/2020)

Related Diseases

1.	Macular Degeneration (Age-Related Maculopathy) 01/01/2023 - "To evaluate the impact of modifying the abicipar pegol (abicipar) manufacturing process on the safety and treatment effect of abicipar in patients with neovascular age-related macular degeneration (nAMD). " 01/01/2020 - "Abicipar pegol for neovascular age-related macular degeneration." 01/01/2019 - "To evaluate comparability of abicipar pegol (abicipar) effects in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) in Japan and the United States. " 07/01/2020 - "Abicipar pegol: an investigational anti-VEGF agent for the treatment of wet age-related macular degeneration." 01/01/2019 - "Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States."
2.	Vascular Diseases (Vascular Disease) 01/01/2017 - "DARPins are being developed for a wide variety of medical applications, and the most studied molecule, abicipar pegol, is used to treat chorioretinal vascular diseases. "
3.	Inflammation (Inflammations) 01/01/2021 - "Abicipar pegol, a designed ankyrin repeat protein (DARPin), demonstrated the ability to maintain stable visual acuity with 12-week dosing, but was not approved by the FDA due to higher than usual rates of intraocular inflammation. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Carrier Proteins (Binding Protein)
3.	Ranibizumab (Lucentis)
4.	Designed Ankyrin Repeat Proteins
5.	Proteins (Proteins, Gene)